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Background: Complete or almost complete recording of reoperations is essential to enable a correct interpretation
of data in arthroplasty registers. The completeness of recordings due to infection is unknown in the Swedish Hip
Arthroplasty Register (SHAR). We therefore used a combination of data from the Swedish Prescribed Drug Register
(SPDR) and studies of medical records to validate the data of reoperations due to infection in the SHAR.
Methods: All patients registered for a primary Total Hip Replacement (THR) in the SHAR between July 1, 2005 and
December 31, 2008 were selected for the study (45,531 patients with 49,219 THRs) and were matched with the
SPDR. All patients with a minimum of 4 weeks of continuous outpatient antibiotic treatment within 2 years after
their primary THR (1,989 patients, with 2,219 THRs) were selected for a medical records review to find the THRs
reoperated due to infection.
Results: 599 (1.3%) of the THRs had been reoperated within 2 years after the index operation and in 47.4% of
these the prosthesis had been revised or extracted. 400 of the THRs were registered for a reoperation in the SHAR
resulting in a completeness of 67%.
Conclusions: The completeness of registration due to early infection after THR questions whether the SHAR
reoperation data can be used in order to evaluate changes in postoperative infection rates.
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National arthroplasty register data is often used to evalu-
ate the outcome after hip replacement surgery. The data
can be used in order to evaluate risks of revision surgery,
the patient reported outcome, mortality and more. The
strengths of register data are the large number of pa-
tients available for inclusion making statistical analyses
robust when evaluating rare competing events, but it
assumes high validity of the data. Validation of national
arthropasty register data is often done by matching data
from health care registries, by investigating medical
journals or by questionnaires answered by patients [1].
Previous studies have demonstrated that the overall
validity of revision surgery is high in many arthroplasty
registries [2-4].* Correspondence: viktor.lindgren@karolinska.se
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unless otherwise stated.Arthroplasty register data has been used to estimate
infection risks after replacement surgery and it has been
postulated that the risk of infection is increasing [5-7].
However, concerns have been raised by Jämsen et al.
regarding the validity of recordings of revision due to in-
fection in the Finnish Arthroplasty Register, and there is
reason to believe that the same might apply to other
registries as well [8].
As part of the ambition to continuously increase the
quality of data in the Swedish Hip Arthroplasty Register
(SHAR), we aimed to evaluate the validity of reopera-
tions due to infection. By matching the data in SHAR
with the Swedish Prescribed Drug Register (SPDR) we
conducted a targeted study of medical records to find
non recorded reoperations due to infection.Methods
The SHAR was started in 1979 and all private and public
orthopaedic units in Sweden voluntary participate. 98% of
all primary Total Hip Replacements (THRs) in Swedenal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Number of tablets/doses required for 4 weeks of
continuous treatment
Antibiotic ATC-code Daily dose 4 weeks
treatment
Amoxicillin J01CA04 750 mg 1×3 84
Amoxicillin and
clavulanic acid
J01CR02 875/125 mg 1×2 56
Azitromycin J01FA10 250 mg 1×1 28
Cefadroxil J01DB05 1 g 1×2 56
Cefalexin J01DB01 3 g 1×2 56
Ceftriaxon J01DD04 2 g 1×1 28
Ceftributen J01DD14 400 mg 1×1 28
Cefuroxim J01DC02 250 mg 1×2 56
Ciprofloxacin J01MA02 250 mg 1×2 56
500 mg 1×2 56
750 mg 1×2 56
Daptomycin J01XX09 400 mg 1×1 28
J01DH03 1 g 1×2 28
Erytromycin J01FA01 250 mg 2×2 112
Fenoximetylpenicillin J01CE02 1 g 2×3 168
Flukloxacillin J01CF05 500 mg 2×3 168
750 mg 2×3 168
Fusidic acid J01XC01 250 mg 2×3 168
Klaritromycin J01FA09 250 mg 1×2 56
Klindamycin J01FF01 300 mg 1×2 56
Levofloxacin J01MA12 500 mg 1×1 28
Linezolid J01XX08 600 mg 1×2 56
Lorakarbef J01DC08 200 mg 1×2 56
Metronidazole P01AB01 400 mg 1×3 84
Moxifloxacin J01MA14 400 mg 1×1 28
Norfloxacin J01MA06 400 mg 1×2 56
Rifampicin J04AB02 600 mg 1×1 28
Roxitromycin J01FA06 150 mg 1×2 56
Sulfametoxazol and
trimetoprim
J01EE01 160 mg/800 mg 1×2 56
Teikoplanin J01XA02 400 mg 1×1 28
Telitromycin J01FA15 400 mg 2×1 56
Vancomycin J01XA01 1 g 1×2 56
(ATC-code = Anatomic Therapeutic Chemical classification-code).
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mation including personal identification number, age, sex,
side, diagnosis and a number of operative details regarding
surgical approach, implant, fixation method etc. Any type
of reoperation as well as the reason for the surgery is to be
reported to the register. The SHAR is connected to the
Swedish Death Register, thereby also including survival
time of implant and patient.
In the SHAR reoperation denotes any kind of subse-
quent surgery of adjacent tissues related to the primary
THR, whereas revision denotes a reoperation including ex-
change of parts or entire prosthesis, or extraction of pros-
thesis. To ensure that reoperations are coded correctly the
operating unit sends a copy of the medical records to the
SHAR for manual centralized imputing.
The SPDR was introduced July 1, 2005 and is a
register to which all pharmacies in Sweden are obliged
to report and automatically include all outpatient
prescribed drugs dispensed in Sweden. The SPDR in-
cludes information regarding the drug, the amount
prescribed, the amount dispensed, the date of pre-
scribing and dispensing, the instruction from the pre-
scribing doctor, the level of care and the speciality of
the prescribing doctor etc. The SPDR is based on the
personal registration number and can therefore be
connected to other national healthcare and quality
registries in order to evaluate for example postopera-
tive infections [10].
The study was given ethical approval by the Regional
Ethical Committee in Gothenburg on 11 October 2010
(ref. 553–10).
All operations between July 1, 2005 and December 31,
2008 reported to the SHAR for a primary THR were in-
cluded in the study (n = 49,219). All diagnoses, bilateral
arthroplasties and all types of implants regardless of the
method of fixation were included. By using the patient’s
personal registration number, the cohort was then
matched with the SPDR for all dispensed antibiotic pre-
scriptions between July 1, 2005 and December 31, 2010.
We limited the search by only including the dispensed
amount of antibiotics suggesting a continuous outpatient
medication for at least 4 weeks of selected antibiotics
with Anatomic Therapeutic Chemical codes (ATC-codes)
J01, J04 and P01 (Table 1). We limited the observation
time to 2 years after the primary THR for each patient.
Antibiotics where the instructions specifically indicated
treatment for other infection (e.g. urinary tract infection,
pneumonia) than a wound or prosthesis related infection
were excluded.
By matching the two registries we found that 1,989
patients with 2,217 THRs had been prescribed and
dispensed >4 weeks of antibiotic treatment within the
first 2 years after the primary THR. A questionnaire for
each of the 2,217 THRs, including a list of dispensedantibiotics, was sent to a doctor at the primary operating
unit (76 different units) to complete and return (Figure 1).
In the questionnaire the receiving doctor were asked
to check each patient’s medical records and report if the
THR had been reoperated due to infection within 2 years.
If so, the type of procedure (wound debridement, irriga-
tion of the prosthesis, exchange of one or more parts, or
extraction of the entire prosthesis) was requested (here-
after called questionnaire data).
Figure 1 Study flowchart. (THR = Total Hip Replacement, SHAR = Swedish Hip Arthroplasty Register, SPDR = Swedish Prescribed Drug Register).
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returned and all orthopaedic clinics contributed. 4 of the
patients had incorrectly been registered in the SHAR as
primary THR when in fact they had a revision THR.
These cases were excluded reducing the final study sam-
ple to 2,187 THAs in 1,959 patients.
The SHAR reoperation database was searched for all
reoperations due to infection within 2 years after the
index THR of all primary THRs between July 1, 2005
and December 31, 2008 (hereafter called SHAR reoper-
ation data).
Each THR was studied separately as one patient could
have more than one THR. Each reoperated THR was
only counted once even though it might have been reop-
erated several times.
Statistics
The cumulative incidence of reoperation due to infec-
tion was calculated by dividing the number of reoperated
THRs (in both questionnaire and SHAR reoperation
data) by the total number of primary THRs in Swedenbetween July 1, 2005 and December 31, 2008 excluding
the THRs in patients that died without reoperation
within 2 years after the primary THR (n = 47,358). Sensi-
tivity, specificity, negative predictive values (NPV), positive
predictive values (PPV) and measurement agreement ac-
cording to Cohen’s Kappa [11] was calculated for the
SHAR reoperation data compared with the questionnaire
data. We used the IBM SPSS Statistical software version
21 for Windows.
Results
A total of 599 primary THRs were identified by the
questionnaire data and the SHAR reoperation data mak-
ing the cumulative incidence of reoperation due to infec-
tion 1.3%. 302 (50%) of the reoperated THRs were found
in both the questionnaire and SHAR reoperation data
and the measurement agreement according to Cohen’s
Kappa was 0.67 (Table 2). The THRs not recorded as
reoperated due to infection in the SHAR (n = 199, 67%)
included all types of reoperations (Table 3). The number
of non-registered reoperations for the individual primary
Table 2 The number of THRs with a reoperation due to
infection found by either of the two methods including
calculated sensitivity, specificity, positive predictive value
(PPV), negative predictive values (NPV) and method
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associated to the total number of reoperated infections
by each unit (Figure 2).
Discussion
This study presents an external validation of the SHAR
reoperation database in terms of reoperation due to in-
fection and shows that 67% of the reoperated infections
are reported to the register.
The strengths of this study are the national coverage
of the SPDR and the number of medical records studied
and returned questionnaires by the operating units. The
study of medical records is also likely to give a more
reliable validation compared to other methods such as
procedure codes in administrative databases (that lack
specificity of side) or questionnaires filled in by patients.
Limitations of the study design are that the validation by
the SPDR requires that the patient had been prescribed
and dispensed outpatient antibiotic treatment for the in-
fection. Therefore patients that died before discharge orTable 3 Type of reoperation due to infection within 2 years a
in the Swedish Hip Arthroplasty Register (SHAR)
Type of reoperation Total
n
Reoperation without revision of prosthesis
Wound revision 103
Irrigation of prosthesis 212
Total 315
Revision of prosthesis
Exchange of parts or entire prosthesis 173
Extraction (with or without spacer) 111
Total 284
Total 599were never prescribed or complying to antibiotic treat-
ment were not identified in the SPDR. Information on pa-
tients that had no follow-up at the primary operating unit
could also be missing in the questionnaire as well as the
risk of reporting bias by the doctors doing the medical re-
cords review. It is therefore possible that the incidence in
this study is an underestimation of the true reoperation
incidence.
The low completeness of registered reoperations due
to infection in the SHAR varied greatly between the op-
erating units, but seems to be a general problem of the
Swedish orthopaedic community. The reason for the low
completeness is probably multifactorial but one important
reason might be that reoperations due to infection with
no or minor implant exchange are performed in an acute
setting and could therefore deviate from the standard
routine reporting. Another reason might be that other
orthopaedic quality registries (e.g. the Swedish Knee
Arthroplasty Register) only record revisions (implant
exchange or extraction) and not all reoperations intro-
ducing an uncertainty in the reporting routines to
the SHAR [12]. The large number (68.8%) of non-
recorded reoperations without implant exchange or
extraction supports this (Table 3). There is also a pos-
sibility that units taking care of their own complica-
tions deliberately fail to report reoperations to the
SHAR in order to improve their results in the SHAR
annual report. However, the high compliance to our
questionnaire, where all operating units participated
speaks against this presumption. There are advantages
of a central monitoring system like a national arthro-
plasty register as the follow up is not limited to the
primary operating unit. This is likely the most import-
ant reason to why 98 of the reoperations identified via
the SHAR reoperation data were missing in the ques-
tionnaire data (Table 2).
Arthroplasty register data has been used to study the

















registered reoperations in SHAR non-registered reoperations in SHAR
Figure 2 Number of registered and non-registered reoperations for each operating unit. Each bar, representing one operating unit,
is divided into registered and non-registered reoperations. All reoperations are due to infection and within 2 years after primary Total
Hip Replacement.
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ture infections that are reoperated (and in some regis-
tries only the revised ones) and not the infections
treated by antibiotics only [13-15]. In Sweden 9% of
deep early and delayed periprosthetic infections are
treated with antibiotics without surgical intervention
[16]. The change in infection rates can therefor reflect a
change in reoperation policy or the change in arthro-
plasty modularity making it easier to revise the pros-
thesis by exchange of head or acetabular liner. The low
completeness found in this study also imply that change
in reporting routines could have a large impact on the
change in infection rates in register data. That only
47.4% of the reoperations due to infection in this study
were revisions, implies that especially those arthroplasty
registers that only record revisions seem less reliable
when studying infection rates as revisions are dependent
on the modularity of the prosthesis (Table 3). In contrast
to previous arthroplasty validation studies that have
found extraction of prosthesis (i.e. Girdlestone proced-
ure) due to infection to be the most common error in
registration, we found this procedure to be the most
reliable of the four categories used by us [1,3]. The
conclusion is that the SHAR data cannot with certainty
be used as an estimation of the total infection burden
after THR.
Although the data in this study only investigates the
number of surgically treated THRs due to infection (i.e.
excluding the non-surgically treated), knowledge about
the true proportion of reoperations is important for both
clinicians and patients when estimating risks before
planning a primary THR.
The validity of a total joint replacement register is
dependent on the coverage and completeness of the
register. The coverage (i.e. the number of operating unitsthat report to a register) is important, but the figures
can be misleading if the completeness (i.e. the number
of correct registrations on an individual level) is low at
some or all operating units. This can lead to both an
underestimation of the true total incidence of reopera-
tions and to an incorrect relative incidence between the
individual reporting units. It is therefore important to
evaluate both coverage and completeness so that the re-
sults can be interpreted with justice.
The control of completeness of primary THRs is stan-
dardized in the SHAR by an annual matching of the reg-
istered primary THRs in the register with the Swedish
National Patient Register (NPR) procedure codes via the
patients’ personal registration number. To guarantee
high quality of the reoperation data in the database the
operating unit sends a copy of the medical records to
the SHAR for manual centralized imputing. Subsequent
interventions, however, are more difficult to automatic-
ally validate by the same method as primaries as there
are many different possible procedure-codes and as the
NPR lacks laterality (left or right hip), making numerous
combinations possible. To control that all subsequent
procedures are reported, the SHAR has newly started a
monitoring system by site visits to the operating units
where the SHAR data is compared to local administra-
tive data and medical records.Conclusions
The completeness of the reoperation data in the SHAR
questions whether data from arthroplasty registers that
record reoperations or revisions as complication out-
come can be used in order to evaluate both non-
surgically and surgically treated infection rates after
THR. An open publication along with feedback to the
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tines in the future.
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